Breaking News Instant updates and real-time market news.

CLSN

Celsion

$2.05

-0.7 (-25.45%)

, HOS

Hornbeck Offshore

09:30
06/16/17
06/16
09:30
06/16/17
09:30

On The Fly: Pre-market Movers

HIGHER: Celsion (CLSN), up 75.6% after filing to withdrawal its registration statement on Form S-1... Hornbeck Offshore (HOS), up 25.4% after it refinanced its existing $200M senior secured revolving credit facility with a new first-lien delayed-draw credit facility providing for up to $300M of term loans... Amazon (AMZN), up 1.5% after announcing it will acquire Whole Foods (WFM) for $42.00 per share... Adamis (ADMP), up 3.5% following FDA approval of its epinephrine syringe. GROCERS DOWN AFTER WHOLE FOODS ACQUISITION NEWS: Kroger (KR), down 11.4%... Sprouts Farmers Market (SFM), down 11.8%... Costco (COST), down 4.5%... Wal-Mart (WMT), down 5.9%... Target (TGT), down 7.9%. ALSO LOWER: Booz Allen (BAH) down 15% after being downgraded to Hold from Buy at Vertical Research... Nike (NKE), down 2.5% after being downgraded to Neutral from Overweight at JPMorgan.

CLSN

Celsion

$2.05

-0.7 (-25.45%)

HOS

Hornbeck Offshore

AMZN

Amazon.com

$964.17

-12.3 (-1.26%)

ADMP

Adamis Pharmaceuticals

$5.75

2 (53.33%)

KR

Kroger

SFM

Sprouts Farmers Market

$22.42

-2.32 (-9.38%)

COST

Costco

$180.06

-1.61 (-0.89%)

WMT

Wal-Mart

TGT

Target

BAH

Booz Allen

NKE

Nike

  • 20

    Jun

  • 22

    Jun

  • 29

    Jun

CLSN Celsion
$2.05

-0.7 (-25.45%)

11/11/16
MAXM
11/11/16
DOWNGRADE
MAXM
Hold
Celsion downgraded to Hold from Buy at Maxim
Maxim analyst Jason McCarthy downgraded Celsion to Hold from Buy given the uncertainty of the Biotechnology market and the company's financing challenges. Celsion is down to just over a quarter's worth of cash remaining on its balance sheet, McCarthy noted.
04/10/17
RODM
04/10/17
INITIATION
Target $1.5
RODM
Buy
Celsion assumed with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis assumed coverage of Celsion with a Buy rating and $1.50 price target.
07/12/16
HCWC
07/12/16
INITIATION
Target $3
HCWC
Buy
Celsion assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Celsion with a Buy rating and $3 price target.
04/10/17
04/10/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Incyte (INCY) initiated with a Buy at Gabelli. 2. Canada Goose (GOOS) initiated with an Overweight at Barclays, while being initiated with an Outperform at BMO Capital, Wells Fargo, Credit Suisse, RBC Capital, and CIBC, a Buy at Goldman and Canaccord, as well as, a Neutral at BofA/Merrill, Nomura, and Baird. 3. Tesaro (TSRO) initiated with a Neutral at Janney Capital. 4. John Bean Technologies (JBT) initiated with an Outperform at BMO Capital. 5. Celsion (CLSN) assumed with a Buy at Rodman & Renshaw. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
HOS Hornbeck Offshore

08/05/16
IBER
08/05/16
DOWNGRADE
IBER
Underperform
Hornbeck Offshore downgraded to Underperform from Sector Perform at Iberia
AMZN Amazon.com
$964.17

-12.3 (-1.26%)

06/15/17
NOMU
06/15/17
NO CHANGE
NOMU
Amazon.com price target raised to $1,100 from $975 at Nomura Instinet
Nomura Instinet analyst Anthony DiClemente says that Amazon's (AMZN) current valuation is "reasonable." The analyst says that, assuming the cloud business is worth $220B, based on a 2020 multiple similar to that given Microsoft (MSFT), while its Prime video business is worth $8B, or 12% of Netflix's (NFLX) current valuation, and its advertising business is worth $27B, or double his estimate of Snap's (SNAP) total valuation, the company's e-commerce business is only being valued at about $210B at current levels. Noting that Wal-Mart (WMT) is currently valued at $280B, the analyst says that Amazon's valuation "is not excessively strencthed." DiClemente raised his 2020 EV/EBITDA multiple for the cloud business to 14x from 13.5x, noting that SAP (SAP), Oracle (ORCL) and Microsoft (MSFT) all had higher multiples at similar points in their histories. The analyst raised his target multiple for Amazon's North America e-commerce business to 13x from 12x, which he says is in-line with Wal-Mart's mean multiple from 1992-2001. He raised his price target on Amazon to $1,100 from $975 and keeps a Buy rating on the stock.
06/16/17
KEYB
06/16/17
NO CHANGE
KEYB
Microsoft to benefit from cloud expansion, says KeyBanc
KeyBanc says that spending on the cloud could triple to $239B within five years, and the firm says that Microsoft (MSFT) "has the most to gain," as it thinks that the company is poised to surpass Amazon (AMZN) to become the sector leader. KeyBanc keeps a $78 price target and an Overweight rating on Microsoft.
06/16/17
FBRC
06/16/17
NO CHANGE
Target $111
FBRC
Outperform
Carter's positioned for multiple expansion, says FBR Capital
FBR Capital analyst Susan Anderson says shares of Carter's (CRI) have been pressured by concerns over exposure to department stores. The analyst, however, believes the department store weakness is more than offset with Amazon/Skip Hop growth. Further, the analyst thinks the company's Q2 is "trending significantly better" than Q1 based on "solid spendtrend data" for children's. She expects Carter's to see multiple expansion and keeps an Outperform rating on the shares with a $111 price target.
06/15/17
06/15/17
NO CHANGE

FANG fundamentals still strong but stocks may moderate, says Canaccord
Canaccord analyst Michael Graham noted the FANG stocks - Facebook (FB),Amazon (AMZN), Netflix (NFLX), and Google parent Alphabet (GOOG) - outpaced the S&P by a great deal and he feels even though fundamentals remain strong, the shares' momentum may begin to moderate. Graham believes most of the growth opportunities in tech remain with the FANG group but he believes valuations are quite reasonable. He downgraded Alphabet to Hold from Buy and believes that Amazon is the one to own long-term.
ADMP Adamis Pharmaceuticals
$5.75

2 (53.33%)

06/15/17
MAXM
06/15/17
NO CHANGE
Target $10
MAXM
Buy
Adamis Pharmaceuticals partnering could be next, says Maxim
Following FDA approval of its epinephrine syringe approval, Maxim said Adamis Pharmaceuticals is now exploring commercialization options and in discussions with potential partners. At just over a $100M in market capitalization, cash on the balance sheet and an alternative to EpiPen, the firm sees the story getting better and reiterates its Buy rating and $10 pic target.
01/24/17
MAXM
01/24/17
NO CHANGE
Target $10
MAXM
Buy
Adamis undervalued if able to take just 10% of EpiPen market, says Maxim
After privately-held Kaleo announced a "complex pricing strategy" for their EpiPen-like device, Auvi-Q, which is returning to the market, Maxim analyst Jason Kolbert said he views Adamis' (ADMP) PFS to be a better, more user friendly product than Mylan's (MYL) EpiPen, Impax Labs' (IPXL) Adrenaclick and Kaleo's AuviQ. If Adamis can acquire just 10% market share, which he believes is at the low end, the shares are undervalued, Kolbert tells investors. He keeps a Buy rating and $10 price target on Adamis shares.
12/20/16
RILY
12/20/16
INITIATION
Target $5
RILY
Buy
Adamis Pharmaceuticals initiated with a Buy at B. Riley
B. Riley analyst Greg Chodaczek started Adamis Pharmaceuticals with a Buy rating and $5 price target. The company has three respiratory products in its development pipeline, representing a $20B opportunity, the analyst contends.
12/19/16
MAXM
12/19/16
NO CHANGE
Target $10
MAXM
Buy
Adamis resubmission sets up mid-year PDUFA for generic EpiPen, says Maxim
Maxim analyst Jason Kolbert said Adamis Pharmaceuticals' (ADMP) resubmission of its New Drug Application for its epinephrine pre-filled syringe, a generic version of Mylan's (MYL) EpiPen, addresses all the issues in the FDA Complete Response Letter and triggers a 30 day review to "accept" the filing, which should be followed by a six month PDUFA date and approval by June of next year, he believes. Adamis' version is more user friendly, design wise, than Mylan's generic and the market opportunity is large, said Kolbert, who thinks that this can become a significant product for the company "even with just moderate market share assumptions." He keeps a Buy rating and $10 price target on Adamis, which he sees as "poised for a breakout" in 2017.
KR Kroger

06/16/17
WELS
06/16/17
NO CHANGE
WELS
Kroger price target lowered to $28 from $35 at Wells Fargo
Wells Fargo cut its price target on Kroger after the company lowered its fiscal 2017 EPS guidance. The firm says that the company's investments in prices was larger than expected amid tough competition. However, Wells believes that the company is taking the necessary steps to preserve its market share, and it believes that the stock can reward patient investors. It keeps an Outperform rating on the shares.
06/16/17
GSCO
06/16/17
DOWNGRADE
Target $26
GSCO
Neutral
Kroger downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Stephen Tanal downgraded Kroger to Neutral from Buy citing the high degree of uncertainty he sees for its earnings beyond this year given competitive disruption, which will increase with the growth of ALDI and Lidl in the U.S. Tanal cut his price target on Kroger to $26 from $33.
06/16/17
GUGG
06/16/17
NO CHANGE
GUGG
Performance Food added to Best Ideas List, Kroger removed at Guggenheim
06/16/17
RBCM
06/16/17
NO CHANGE
RBCM
Kroger risk/reward 'favorable,' says RBC Capital
After Kroger lowered its fiscal 2017 EPS guidance. RBC Capital analyst William Kirk says that the company's increased investments in prices and labor are "alarming." However, the analyst notes that the company still had positive ID sales so far this quarter, and he thinks that it will benefit from the closure of a number of competing stores. He says that the stock's risk/reward ratio is positive, and he keeps an Outperform rating on the stock.
SFM Sprouts Farmers Market
$22.42

-2.32 (-9.38%)

06/15/17
MSCO
06/15/17
DOWNGRADE
MSCO
Equal Weight
Sprouts Farmers Market downgraded to Equal Weight at Morgan Stanley
05/15/17
LOOP
05/15/17
INITIATION
Target $25
LOOP
Hold
Sprouts Farmers Market initiated with a Hold at Loop Capital
Loop Capital analyst Andrew Wolf initiated Sprouts Farmers Market with a Hold rating and $25 price target, as he believes the company has a powerful business model and solid store-level execution but he expects deep food-price deflation to continue to drag on profit gains in the intermediate term.
05/02/17
RBCM
05/02/17
NO CHANGE
RBCM
Sprouts Farmers Q1 results likely to beat expectations, says RBC Capital
RBC Capital analyst William Kirk expects Sprouts' Q1 results to beat expectations by a small amount, as he believes that its Q1 guidance is "very conservative." He reiterates a $28 price target and an Outperform rating on the shares.
06/15/17
06/15/17
DOWNGRADE
Target $23

Equal Weight
Sprouts Farmers Market downgraded on valuation at Morgan Stanley
As previously reported, Morgan Stanley downgraded Sprouts Farmers Market to Equal Weight from Overweight with a $23 price target. Analyst Vincent Sinisi now believes shares are fairly valued for future growth potential and would look for signs of a margin rebound before becoming more constructive again.
COST Costco
$180.06

-1.61 (-0.89%)

05/01/17
CLVD
05/01/17
NO CHANGE
CLVD
Costco April sales slightly softer versus March, says Cleveland Research
Cleveland Research said Costco's April sales are slightly softer versus March ex-Easter shift, but still in line with channel expectations. The firm said Costco has been focused on price/value recently, which could incrementally pressure gross margins.
04/21/17
04/21/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Costco (COST) upgraded to Overweight from Equal Weight at Barclays with analyst Karen Short citing a survey by the firm where results showed analytically that Costco (COST) is "very protected" from Amazon (AMZN). 2. CSX (CSX) was upgraded to Buy from Hold at Aegis and to Outperform from Market Perform at Raymond James. 3. Gigamon (GIMO) upgraded to Buy from Hold at Stifel with analyst Patrick Newton citing valuation and his belief that the company has a number of potential positive catalysts, including the 100G upgrade cycle at T-Mobile (TMUS), in-line SSL decryption, and the potential for reduced competition from Ixia (XXIA). 4. Skechers (SKX) upgraded to Buy from Neutral at B. Riley with analyst Jeff Van Sinderen citing "strong" international growth and worldwide comps following the company's better than expected first quarter results. The analyst raised his price target for the shares to $32 from $28. 5. Quest Diagnostics (DGX) upgraded to Outperform from Market Perform at Raymond James with analyst Nicholas Jansen saying Quest has delivered two strait quarters of high single digit adjustment EBIT growth and sees room for sustained mid-to-high single digit growth driven by improved commercial execution, strengthening health system relationships and outreach deals, and invigorate programs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/21/17
LEHM
04/21/17
UPGRADE
Target $185
LEHM
Overweight
Costco upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Karen Short upgraded Costco Wholesale (COST) to Overweight after her survey of 800 customers indicated more than 80% of them go to Costco stores specifically for food. This suggests the company is "very protected" from Amazon (AMZN), Short tells investors in a research note. The analyst expects Costco's traffic to accelerate amid easing comparisons into the second half of the year. Short also sees the potential for a special dividend from a tax break on foreign cash repatriation. She raised her price target for the shares to $185 from $170.
05/26/17
FBCO
05/26/17
NO CHANGE
Target $195
FBCO
Outperform
Costco price target raised to $195 after 'bounce-back quarter' at Credit Suisse
Credit Suisse analyst Edward Kelly noted that Costco followed up a "disappointing" Q2 performance with a "much better" Q3, noting that its new card continued to contribute while core merchandise margin also improved and fuel turned into a tailwind. The quarterly report was "clearly positive," comparisons remain fairly easy in the near-term and Costco's performance is notable given the landscape of other "structurally challenged retail names," which suggests the stock could still have legs, Kelly tells investors. He raised his price target to $195 from $187 and keeps an Outperform rating on Costco shares.
WMT Wal-Mart

05/31/17
BARD
05/31/17
NO CHANGE
Target $85
BARD
Outperform
Wal-Mart e-commerce coming into focus, says Baird
Baird analyst Peter Benedict noted upcoming Wal-Mart events that will give the company the chance to provide a baseline on its e-commerce operation. The analyst noted the operation is beginning to show some encouraging signs despite profitability remaining in flux. He noted the upcoming shareholder's meeting and the Baird conference as two opportunities that are imminent. Benedict reiterated his Outperform rating and $85 price target on Wal-Mart shares.
05/19/17
COWN
05/19/17
NO CHANGE
Target $83
COWN
Outperform
Wal-Mart e-commerce business remains in early innings, says Cowen
Cowen analyst Oliver Chen said Wal-Mart continues to execute in a difficult retail environment. He noted e-commerce sales were up 63% during the quarter and he believes they remain in the early innings. Chen believes Wal-Mart will continue to innovate and execute and thus reiterated his Outperform rating and $83 price target on Wal-Mart shares.
05/19/17
BMOC
05/19/17
UPGRADE
BMOC
Market Perform
Wal-Mart upgraded on outlook improvement at BMO Capital
As noted earlier, BMO Capital upgraded Wal-Mart to Market Perform from Underperform. Analyst Wayne Hood says the outlook of the company's sales and transaction growth has improved in the wake of its Q1 results. However, he adds that the retailer continues to face "many challenges." Target to $80 from $63.
TGT Target

05/17/17
BARD
05/17/17
NO CHANGE
Target $55
BARD
Neutral
Target Q1 results a positive step, but visibility still low, says Baird
Baird analyst Peter Benedict said Target's Q1 earnings beat was "a step in the right direction," but he adds that the bar was low and visibility remain limited. Week-to-week results remain volatile and driving positive comps remains the key for a re-rating of the stock, contends Benedict, who keeps a Neutral rating and $55 price target on Target shares.
03/01/17
BERN
03/01/17
NO CHANGE
BERN
Dollar General unlikely to be affected by Target price cuts, says Bernstein
Bernstein analyst Brandon Fletcher says that Dollar General's (DG) stock fell due to worries about Target's (TGT) price cuts. however, Fletcher does not believe that there is significant overlap between the two companies' customer base or between their geographic markets, so he does not expect Dollar General to be signficantly affected by Targets moves. The analyst keeps a $91 price target and an Outperform rating on Dollar General.
03/01/17
WOLF
03/01/17
DOWNGRADE
WOLF
Underperform
Target downgraded to Underperform from Peer Perform at Wolfe Research
05/09/17
CLVD
05/09/17
NO CHANGE
CLVD
Neutral
Target Q1 comps likely ahead, but outlook remains cautious, says Cleveland
Cleveland Research analyst Scott Bender said Target sales appear to have improved in Q1 against easier comps and sees upside to consensus comp expectations for the quarter. However, the channel outlook remains cautious as there are concerns that EDLP could hurt sales, and the merchandising re-organization could cause disruptions. Bender has a Neutral rating on Target.
BAH Booz Allen

06/16/17
VERT
06/16/17
DOWNGRADE
VERT
Hold
Booz Allen downgraded to Hold from Buy at Vertical Research
06/16/17
RAJA
06/16/17
DOWNGRADE
RAJA
Market Perform
Booz Allen downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Brian Gersuale downgraded Booz Allen following the last night's announcement that the Department of Justice is investigating the company for its indirect billing practices. The analyst expects the next year or more will be filled with investor insecurity to understand the financial and operational impact from the investigation.
06/16/17
WELS
06/16/17
NO CHANGE
WELS
Booz Allen still has multiple positive catalysts, says Wells Fargo
After Booz Allen announced that the Department of Justice was conducting a civil and criminal probe of its accounting and charging practices involving the government, Wells Fargo says that past legal/political issues involving the company have given investors good opportunities to buy the stock at attractive prices. The firm notes that the company has not been indicted. Wells remains upbeat on the company's strong brand, market positioning,and ability to benefit from "unusually strong government fiscal year-end award activity." Wells trimmed its price target on the shares to $40 from $43 but keeps an Outperform rating.
06/16/17
SBSH
06/16/17
NO CHANGE
Target $41
SBSH
Neutral
Citi sees 'more questions than answers' for Booz Allen
Citi analyst Jonathan Raviv sees "more questions than answers" after Booz Allen Hamilton disclosed a Department of Justice civil and criminal investigation relating to elements of the company's cost accounting and indirect cost charging practices. A share selloff is warranted as the disclosure "takes some shine off, especially for a stock that has typically traded at a premium," Raviv tells investors in a research note. He notes that an 8% yield to his FY19 free cash flow per share estimate yields a $28 stock. The analyst has a Neutral rating on Booz Allen with a $41 price target. The stock in premarket trading is down 16%, or $6.23, to $33.10.
NKE Nike

06/16/17
BARD
06/16/17
NO CHANGE
Target $62
BARD
Outperform
Nike restructuring a replay of 2009, suggests buying opportunity, says Baird
Baird analyst Jonathan Komp noted Nike has undergone multiple restructurings, stating that the current one appears to be a replay of its 2009 strategy, which resulted in a very strong multi-year stretch of outperformance for the stock. The analyst said the playbook suggest a compelling buying opportunity post Q4 earnings. Komp maintained his Outperform rating and $62 price target on Nike shares.
06/01/17
PIPR
06/01/17
NO CHANGE
Target $50
PIPR
Neutral
Piper 'firmly' believes too early to buy Nike shares
Piper Jaffray analyst Erinn Murphy believes Nike's innovation pipeline "has paused" while competition "remains fierce." The analyst "firmly" believes it remains too early to buy Nike shares. To reflect further gross margin pressures and currency moves, the analyst lowered her FY18 earnings estimate to $2.40 from $2.44 and price target to $50 from $51. Murphy expects Nike management, in due course, will lower their long-term targets. She keeps a Neutral rating on the shares.
06/16/17
JPMS
06/16/17
DOWNGRADE
Target $58
JPMS
Neutral
Nike downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Matthew Boss downgraded Nike to Neutral and lowered his price target for the shares to $58 from $61. The footwear giant closed yesterday down 3%, or $1.76, to $52.90. The analyst's work suggests Nike's sales in North America are likely to get worse before getting better. The company changes announced this week will take time, Boss tells investors in a research note. The analyst, however, is "encouraged" by management's cost reductions and "forward thinking initiatives."
06/13/17
ARGS
06/13/17
DOWNGRADE
ARGS
Hold
Foot Locker downgraded to Hold from Buy at Argus
Argus analyst John Staszak downgraded Foot Locker (FL) based on weakening demand for Nike (NKE) footwear. The analyst says that Nike footwear generates more than two-thirds of Foot Locker's revenue, and he thinks that the retailer will have difficulty reaching 5% comp sales growth in the second half of fiscal 2018.

TODAY'S FREE FLY STORIES

UAA

Under Armour

$17.37

-0.42 (-2.36%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Technical Analysis
Technical View: Under Armour falls, analyst action »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

CAH

Cardinal Health

$67.07

-0.43 (-0.64%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Initiation
Cardinal Health initiated  »

Cardinal Health initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

HAS

Hasbro

$93.24

-1.6 (-1.69%)

, MAT

Mattel

$14.87

-0.99 (-6.24%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Hot Stocks
Toys"R"Us confirms filing Chapter 11 bankruptcy petitions in U.S. »

Toys"R"Us…

HAS

Hasbro

$93.24

-1.6 (-1.69%)

MAT

Mattel

$14.87

-0.99 (-6.24%)

JAKK

JAKKS Pacific

$2.85

-0.2 (-6.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

, FB

Facebook

$170.01

-1.63 (-0.95%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Recommendations
Amazon.com, Facebook, Alphabet, Alphabet Class A, Activision Blizzard, Electronic Arts, Take-Two analyst commentary  »

KeyBanc remains positive…

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

FB

Facebook

$170.01

-1.63 (-0.95%)

GOOG

Alphabet

$915.00

-5.29 (-0.57%)

GOOGL

Alphabet Class A

$929.75

-5.54 (-0.59%)

ATVI

Activision Blizzard

$64.20

-0.8 (-1.23%)

EA

Electronic Arts

$119.96

0.54 (0.45%)

TTWO

Take-Two

$100.82

0.43 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

ACDVF

Air Canada

$19.26

-0.7713 (-3.85%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Conference/Events
Air Canada to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

XLRN

Acceleron

$39.38

-0.53 (-1.33%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Conference/Events
Acceleron to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

BIG

Big Lots

$49.05

-0.97 (-1.94%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Conference/Events
Big Lots to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 27

    Sep

CALD

Callidus Software

$26.05

0.55 (2.16%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Conference/Events
Callidus Software to host analyst day »

Analyst Day to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ONB

Old National Bancorp

$16.70

0.3 (1.83%)

07:24
09/19/17
09/19
07:24
09/19/17
07:24
Upgrade
Old National Bancorp rating change  »

Old National Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABC

AmerisourceBergen

$80.67

-0.93 (-1.14%)

07:24
09/19/17
09/19
07:24
09/19/17
07:24
Initiation
AmerisourceBergen initiated  »

AmerisourceBergen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

MDGS

Medigus

$2.03

0.08 (4.10%)

07:22
09/19/17
09/19
07:22
09/19/17
07:22
Technical Analysis
Technical View: Medigus moves up sharply in early trading »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBA

Walgreens Boots Alliance

$82.60

0.1 (0.12%)

07:21
09/19/17
09/19
07:21
09/19/17
07:21
Initiation
Walgreens Boots Alliance initiated  »

Walgreens Boots Alliance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

CMG

Chipotle

$301.87

-11.22 (-3.58%)

07:21
09/19/17
09/19
07:21
09/19/17
07:21
Periodicals
Customers criticize Chipotle's 'queso' dip on social media, Reuters reports »

Shares of Chipotle are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTO

ZTO Express

$14.89

-0.18 (-1.19%)

07:20
09/19/17
09/19
07:20
09/19/17
07:20
Initiation
ZTO Express initiated  »

ZTO Express initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$16.75

0.64 (3.97%)

07:20
09/19/17
09/19
07:20
09/19/17
07:20
Hot Stocks
Synchronoss drops 12% after Siris withdraws acquisition interest »

Siris Capital Group on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$16.75

0.64 (3.97%)

07:19
09/19/17
09/19
07:19
09/19/17
07:19
Technical Analysis
Technical View: Synchronoss falls sharply after Siris drops all-cash offer »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$83.31

0.14 (0.17%)

07:18
09/19/17
09/19
07:18
09/19/17
07:18
Initiation
CVS Health initiated  »

CVS Health initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 17

    Oct

MZOR

Mazor Robotics

$46.99

2.29 (5.12%)

07:16
09/19/17
09/19
07:16
09/19/17
07:16
Hot Stocks
Migdal takes 4.92% passive stake in Mazor Robotics »

Migdal Insurance &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

THS

TreeHouse

$67.29

0.08 (0.12%)

07:15
09/19/17
09/19
07:15
09/19/17
07:15
Initiation
TreeHouse initiated  »

TreeHouse reinstated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBC

Wabco

, MTOR

Meritor

$24.35

1.77 (7.84%)

07:15
09/19/17
09/19
07:15
09/19/17
07:15
Recommendations
Wabco, Meritor analyst commentary  »

Wabco price target raised…

WBC

Wabco

MTOR

Meritor

$24.35

1.77 (7.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USAS

Americas Silver

$4.15

-0.36 (-7.98%)

07:15
09/19/17
09/19
07:15
09/19/17
07:15
Recommendations
Americas Silver analyst commentary  »

Americas Silver price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

07:15
09/19/17
09/19
07:15
09/19/17
07:15
General news
FX Update: The dollar has traded mixed »

FX Update: The dollar has…

AAPL

Apple

$158.67

-1.21 (-0.76%)

07:14
09/19/17
09/19
07:14
09/19/17
07:14
Periodicals
Apple Watch Series 3 takes 80%-90% of preorders, AI reports »

The LTE-enabled Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CERN

Cerner

$69.30

-2.18 (-3.05%)

07:13
09/19/17
09/19
07:13
09/19/17
07:13
Initiation
Cerner initiated  »

Cerner initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPP

Hudson Pacific

$31.81

-0.21 (-0.66%)

07:12
09/19/17
09/19
07:12
09/19/17
07:12
Initiation
Hudson Pacific initiated  »

Hudson Pacific initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.